MCID: NPH018
MIFTS: 55

Nephrogenic Systemic Fibrosis

Categories: Rare diseases, Skin diseases, Nephrological diseases

Aliases & Classifications for Nephrogenic Systemic Fibrosis

MalaCards integrated aliases for Nephrogenic Systemic Fibrosis:

Name: Nephrogenic Systemic Fibrosis 53 59 73
Nephrogenic Fibrosing Dermopathy 53 59 73
Nfd 53
Nsf 53

Classifications:

Orphanet: 59  
Rare skin diseases


External Ids:

Orphanet 59 ORPHA137617
UMLS via Orphanet 74 C1619692 C3888044

Summaries for Nephrogenic Systemic Fibrosis

NIH Rare Diseases : 53 Nephrogenic systemic fibrosis is a condition that affects different parts of the body, particularly the skin. Symptoms of the condition may include progressive swelling and tightening of the skin, sometimes resulting in contractures, and pruritis (itching).  The skin findings are similar to those seen in patients with scleroderma.  Nephrogenic systemic fibrosis was first described in 1997. Being exposed to gadolinium-containing contrast agents during MRI testing has been identified as a significant risk factor for development of this disease.

MalaCards based summary : Nephrogenic Systemic Fibrosis, also known as nephrogenic fibrosing dermopathy, is related to keloids and neuronal intranuclear inclusion disease, and has symptoms including exanthema and pruritus. An important gene associated with Nephrogenic Systemic Fibrosis is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Ferrosoferric Oxide and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and eye, and related phenotypes are cardiovascular system and cellular

Wikipedia : 76 Nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD) is a rare and serious... more...

Related Diseases for Nephrogenic Systemic Fibrosis

Diseases related to Nephrogenic Systemic Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 keloids 30.0 SMAD2 SMAD3 SMAD7 TGFB1
2 neuronal intranuclear inclusion disease 11.2
3 tetanus 11.1
4 infant botulism 10.9
5 epileptic encephalopathy, early infantile, 15 10.9
6 hypochondrogenesis 10.4 SMAD2 SMAD3 SMAD7
7 calcific tendinitis 10.4 EDNRA SPP1 TGFB1
8 pauci-immune glomerulonephritis 10.3 CTGF SMAD2
9 clear cell adenocarcinoma 10.3 SMAD2 SMAD3 SMAD4
10 kidney disease 10.3
11 diabetic foot ulcers 10.3 TGFB1 TIMP1
12 sialolithiasis 10.3 CTGF SPP1 TGFB1
13 chronic kidney failure 10.1
14 liver disease 10.1
15 perinephritis 10.0 EDN1 EDNRA
16 demyelinating disease 10.0 CCL7 CXCL2 SPP1
17 idiopathic interstitial pneumonia 10.0 CTGF EDN1 TGFB1
18 transient cerebral ischemia 10.0
19 ischemia 10.0
20 cerebritis 10.0
21 sarcoma 9.9
22 inflammatory breast carcinoma 9.9
23 scleredema 9.9
24 scleromyxedema 9.9
25 mandibulofacial dysostosis with alopecia 9.9 EDN1 EDNRA
26 systemic scleroderma 9.9 CTGF EDN1 TGFB1
27 gingival disease 9.9 CTGF TGFB1 TIMP1
28 hypertrophic scars 9.9 SMAD2 SMAD3 TGFB1 TIMP1
29 vitreoretinopathy, neovascular inflammatory 9.9 CTGF TGFB1 TIMP1
30 gingival fibromatosis 9.9 CTGF TGFB1 TIMP1
31 retinitis 9.8
32 neuronitis 9.8
33 retinitis pigmentosa 9.8
34 cocaine dependence 9.8
35 leber congenital amaurosis 4 9.8
36 depression 9.8
37 penile disease 9.8 DCN SMAD2 SMAD3 TGFB1
38 hepatitis 9.8
39 myopathy 9.8
40 histiocytoma 9.8
41 spinal cord injury 9.8
42 fibrous histiocytoma 9.8
43 calciphylaxis 9.8
44 lymphoma 9.8
45 respiratory failure 9.8
46 kaposi sarcoma 9.8
47 vasculitis 9.8
48 scleroderma, familial progressive 9.8
49 pure red-cell aplasia 9.8
50 meningitis 9.8

Graphical network of the top 20 diseases related to Nephrogenic Systemic Fibrosis:



Diseases related to Nephrogenic Systemic Fibrosis

Symptoms & Phenotypes for Nephrogenic Systemic Fibrosis

UMLS symptoms related to Nephrogenic Systemic Fibrosis:


exanthema, pruritus

MGI Mouse Phenotypes related to Nephrogenic Systemic Fibrosis:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 SMAD2 F13A1 SMAD7 MAPKAP1 PIK3CA SMAD4
2 cellular MP:0005384 10.4 SMAD3 EDNRA MAPKAP1 SMAD2 EPO PIK3CA
3 homeostasis/metabolism MP:0005376 10.4 SMAD3 F13A1 SMAD2 PIK3CA EPO SMAD4
4 growth/size/body region MP:0005378 10.39 SMAD3 MAPKAP1 SMAD2 PIK3CA SMAD4 DCN
5 endocrine/exocrine gland MP:0005379 10.37 SMAD2 F13A1 SMAD7 PIK3CA SMAD4 SMAD3
6 mortality/aging MP:0010768 10.36 SMAD2 F13A1 MAPKAP1 PIK3CA SMAD4 EPO
7 embryo MP:0005380 10.31 SMAD3 SMAD2 MAPKAP1 PIK3CA EPO SMAD4
8 hematopoietic system MP:0005397 10.31 F13A1 SMAD3 EDNRA SMAD2 EPO SMAD4
9 behavior/neurological MP:0005386 10.3 SMAD4 SMAD3 EDNRA SMAD2 PIK3CA DCN
10 immune system MP:0005387 10.29 SMAD4 SMAD3 EDNRA SMAD2 PIK3CA EPO
11 craniofacial MP:0005382 10.28 SMAD2 SMAD4 SMAD3 EDNRA CTGF EDN1
12 integument MP:0010771 10.24 SMAD3 SMAD2 PIK3CA EPO SMAD4 EDNRA
13 digestive/alimentary MP:0005381 10.23 SMAD3 EDNRA SMAD2 SMAD4 DCN CTGF
14 muscle MP:0005369 10.09 EDNRA PIK3CA EPO SMAD4 DCN EDN1
15 neoplasm MP:0002006 10.06 SMAD3 SMAD2 PIK3CA SMAD4 DCN TGM2
16 liver/biliary system MP:0005370 10.02 SMAD4 SMAD3 SMAD2 EPO CTGF TGFB1
17 normal MP:0002873 9.97 SMAD4 EDNRA SMAD2 EPO DCN CTGF
18 reproductive system MP:0005389 9.96 SMAD4 F13A1 SMAD3 SMAD2 PIK3CA DCN
19 renal/urinary system MP:0005367 9.92 SMAD4 SMAD3 EDNRA DCN EDN1 SPP1
20 respiratory system MP:0005388 9.81 F13A1 EDNRA SMAD2 EPO DCN CTGF
21 skeleton MP:0005390 9.73 SMAD2 PIK3CA EPO SMAD4 SMAD3 EDNRA
22 vision/eye MP:0005391 9.23 SMAD3 MAPKAP1 EDNRA SMAD2 PIK3CA DCN

Drugs & Therapeutics for Nephrogenic Systemic Fibrosis

Drugs for Nephrogenic Systemic Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Ferrosoferric Oxide Phase 4,Phase 3,Phase 1
2 Hematinics Phase 4,Phase 3,Phase 1
3 Parenteral Nutrition Solutions Phase 4,Phase 3,Phase 1
4 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
5 Imatinib Mesylate Phase 3,Phase 2 220127-57-1 123596
6 Liver Extracts Phase 3
7 Protein Kinase Inhibitors Phase 3,Phase 2
8 Plasma-lyte 148 Phase 1, Phase 2
9
Iodine Approved, Investigational 7553-56-2 807
10 cadexomer iodine

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Primovist / Eovist in Renally Impaired Patients Completed NCT00908596 Phase 4 Gadoxetic acid disodium (Primovist, BAY86-4873)
2 Safety of Gadovist in Renally Impaired Patients Completed NCT00828737 Phase 4 Gadobutrol (Gadovist, BAY86-4875)
3 Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI) Completed NCT00908310 Phase 4 Omniscan
4 Ferumoxytol Enhanced Magnetic Resonance Angiography in Chronic Kidney Disease Recruiting NCT02997046 Phase 4
5 Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease Recruiting NCT02752191 Phase 4 ferumoxytol;gadofosveset
6 Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) Terminated NCT01078987 Phase 4
7 Nephrogenic Systemic Fibrosis With Gadollinum Unknown status NCT01359345 Phase 2, Phase 3 gadollinum
8 Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec Completed NCT00981942 Phase 3 Imatinib mesylate (Glivec)
9 Efficacy and Safety of Primovist in Chinese Patients Completed NCT00526188 Phase 3 Gadoxetic Acid Disodium (Primovist, BAY86-4873)
10 Ferumoxytol for Magnetic Resonance Imaging in Patients With Severe Kidney Disease Enrolling by invitation NCT02954510 Phase 3 ferumoxytol
11 Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis Completed NCT00677092 Phase 2 Imatinib mesylate
12 The Effect of Crystalloids and Colloids on Visceral Blood Flow Completed NCT01087853 Phase 1, Phase 2 Crystalloid;Colloid
13 MRA With Feraheme in HHT Recruiting NCT02977637 Phase 1
14 Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels Completed NCT01014754
15 Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis Completed NCT00869479
16 Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR Completed NCT01135316 Ablavar
17 Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist Completed NCT00744939 Gadopentetate dimeglumine (Magnevist, BAY86-4882)
18 Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA) Completed NCT00773409
19 Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease Completed NCT00600834
20 Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease Completed NCT00600951
21 Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration Completed NCT01467271
22 Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study) Completed NCT01523873
23 Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced) Completed NCT01132339
24 Magnevist Post-marketing Surveillance in Japan Completed NCT01376739 Gadopentetate dimeglumine (Magnevist, BAY86-4882)
25 Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control Recruiting NCT03108378
26 Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury Recruiting NCT01910818 Not Applicable
27 Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection Withdrawn NCT00811863

Search NIH Clinical Center for Nephrogenic Systemic Fibrosis

Genetic Tests for Nephrogenic Systemic Fibrosis

Anatomical Context for Nephrogenic Systemic Fibrosis

MalaCards organs/tissues related to Nephrogenic Systemic Fibrosis:

41
Skin, Kidney, Eye, Testes, Liver, Bone, Heart

Publications for Nephrogenic Systemic Fibrosis

Articles related to Nephrogenic Systemic Fibrosis:

(show top 50) (show all 436)
# Title Authors Year
1
10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016. ( 29547493 )
2018
2
Letter on 'European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis'. ( 29283443 )
2018
3
Notice of Withdrawal: MR Imaging and Gadolinium: Reassessing the Risk of Nephrogenic Systemic Fibrosis in Patients with Severe Renal Disease. ( 29261455 )
2018
4
Nephrogenic systemic fibrosis: A 15-year retrospective study at a single tertiary care center. ( 28318680 )
2017
5
No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease. ( 28731375 )
2017
6
Nephrogenic systemic fibrosis. ( 28680623 )
2017
7
Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation. ( 28738858 )
2017
8
Prophylactic Hemodialysis for Protection Against Gadolinium-Induced Nephrogenic Systemic Fibrosis: A Doll's House. ( 28501073 )
2017
9
Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana. ( 28965904 )
2017
10
Gadolinium-Naive Nephrogenic Systemic Fibrosis of Breast Mimicking Inflammatory Breast Carcinoma. ( 28323787 )
2017
11
A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR. ( 29025775 )
2017
12
Gadolinium-Induced Nephrogenic Systemic Fibrosis. ( 29744004 )
2017
13
Photopheresis Provides Significant Long-Lasting Benefit in Nephrogenic Systemic Fibrosis. ( 28695022 )
2017
14
European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. ( 28786499 )
2017
15
GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review. ( 28900045 )
2017
16
Nephrogenic systemic fibrosis: fibrotic plaques and contracture following exposure to gadolinium-based contrast media. ( 27073153 )
2016
17
Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1. ( 26802069 )
2016
18
Interaction of Gd-DTPA with phosphate and phosphite: toward the reaction intermediate in nephrogenic systemic fibrosis. ( 26906409 )
2016
19
Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2. ( 26802070 )
2016
20
Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. ( 26885631 )
2016
21
Half-dose gadoxetic acid-enhanced liver magnetic resonance imaging in patients at risk for nephrogenic systemic fibrosis. ( 25591579 )
2015
22
Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis. ( 26305890 )
2015
23
Nephrogenic Systemic Fibrosis on Mammography. ( 25858556 )
2015
24
An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. ( 26076348 )
2015
25
Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? ( 25875973 )
2015
26
Nephrogenic systemic fibrosis following gadolinium administration. ( 26244362 )
2015
27
Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(Ar)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? ( 25651409 )
2015
28
Do ASARM peptides play a role in nephrogenic systemic fibrosis? ( 26336161 )
2015
29
Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model. ( 26138357 )
2015
30
Nephrogenic Systemic Fibrosis Risk After Liver Magnetic Resonance Imaging With Gadoxetate Disodium in Patients With Moderate to Severe Renal Impairment: Results of a Prospective, Open-Label, Multicenter Study. ( 25756684 )
2015
31
Diagnosis of Nephrogenic Systemic Fibrosis by means of Elemental Bioimaging and Speciation Analysis. ( 25708271 )
2015
32
Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium. ( 26017458 )
2015
33
Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. ( 25654421 )
2015
34
Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. ( 26295633 )
2015
35
Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. ( 24477507 )
2014
36
Current status of nephrogenic systemic fibrosis. ( 24582176 )
2014
37
Superior vena cava obstruction associated with nephrogenic systemic fibrosis. ( 24809889 )
2014
38
Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the prospective fibrose nephrogAcnique systAcmique study. ( 24169070 )
2014
39
Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. ( 25048859 )
2014
40
Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media. ( 25036056 )
2014
41
Perforating osteoma cutis in the setting of longstanding nephrogenic systemic fibrosis. ( 24962809 )
2014
42
Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. ( 24706993 )
2014
43
Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. ( 24811860 )
2014
44
Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. ( 24903851 )
2014
45
Nephrogenic systemic fibrosis risk and liver disease. ( 24778878 )
2014
46
Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a research on adverse drug events and reports (RADAR) report. ( 25230161 )
2014
47
The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. ( 25257840 )
2014
48
Nephrogenic systemic fibrosis in a gadolinium-naA^ve patient: Successful treatment with oral sirolimus. ( 25330850 )
2014
49
Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. ( 22898683 )
2013
50
Nephrogenic systemic fibrosis in denmark- a nationwide investigation. ( 24349178 )
2013

Variations for Nephrogenic Systemic Fibrosis

Expression for Nephrogenic Systemic Fibrosis

Search GEO for disease gene expression data for Nephrogenic Systemic Fibrosis.

Pathways for Nephrogenic Systemic Fibrosis

Pathways related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 CCL7 CXCL2 EDN1 EDNRA EPO SMAD3
2
Show member pathways
13.5 CCL7 CTGF EPO SMAD2 SMAD3 SMAD4
3
Show member pathways
13.3 CCL7 CTGF CXCL2 SMAD3 SMAD4 TGFB1
4
Show member pathways
13.01 CXCL2 PIK3CA SMAD2 SMAD3 SPP1 TGFB1
5
Show member pathways
12.85 PIK3CA SMAD2 SMAD3 SMAD4 TGFB1
6 12.84 EDNRA EPO PIK3CA SMAD2 SMAD3 SMAD4
7
Show member pathways
12.82 SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
8
Show member pathways
12.76 PIK3CA SMAD2 SMAD3 SMAD4 TGFB1
9
Show member pathways
12.57 CXCL2 PIK3CA SMAD3 SMAD4 TGFB1
10
Show member pathways
12.53 PIK3CA SMAD2 SMAD3 SMAD4 TGFB1
11
Show member pathways
12.5 SMAD2 SMAD3 SMAD4 TGFB1
12
Show member pathways
12.46 SMAD2 SMAD3 SMAD4 TGFB1
13 12.44 PIK3CA SMAD2 SMAD3 SMAD4 TGFB1
14
Show member pathways
12.43 SMAD2 SMAD3 SMAD4 TGFB1
15 12.36 SMAD2 SMAD3 SMAD4 TGFB1
16
Show member pathways
12.35 SMAD2 SMAD3 SMAD4 SMAD7
17
Show member pathways
12.31 SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
18 12.3 DCN PIK3CA SMAD2 TGFB1
19
Show member pathways
12.26 SMAD2 SMAD3 SMAD4 TGFB1
20 12.25 CTGF SMAD2 SMAD3 SMAD4 TGFB1
21
Show member pathways
12.23 SMAD2 SMAD3 SMAD4 TGFB1
22 12.18 SMAD2 SMAD3 SMAD4 TGFB1
23 12.17 PIK3CA SMAD2 SMAD3 TGFB1
24
Show member pathways
12.11 PIK3CA SMAD2 SMAD3 SMAD4 TGFB1
25 12.1 CTGF SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
26 12.09 PIK3CA SMAD2 SMAD3 SMAD4
27 12.09 CTGF SMAD2 SMAD3 SMAD4 SPP1
28 12.07 SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
29 12.06 SMAD2 SMAD3 SMAD4 TGFB1
30 12 PIK3CA SMAD3 SMAD4 TGFB1
31 11.93 CXCL2 EDN1 PIK3CA
32 11.93 EDN1 EPO PIK3CA TIMP1
33 11.92 SMAD3 SMAD4 TGFB1
34 11.92 SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
35
Show member pathways
11.89 SMAD2 SMAD3 SMAD4 TGFB1
36 11.84 EDN1 PIK3CA SMAD2 SMAD3 SMAD4 TGFB1
37
Show member pathways
11.82 CCL7 CTGF PIK3CA SMAD2 SMAD3 SMAD4
38
Show member pathways
11.79 SMAD2 SMAD3 SMAD4 TGFB1
39 11.79 SMAD2 SMAD3 SMAD4 SMAD7
40 11.73 SMAD2 SMAD3 SMAD4
41 11.73 SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
42 11.72 DCN SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
43 11.7 EDN1 EPO SMAD3 SMAD4
44
Show member pathways
11.7 SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
45 11.56 SMAD3 SMAD4 TGFB1
46
Show member pathways
11.54 SMAD2 SMAD3 SMAD4
47
Show member pathways
11.5 SMAD2 SMAD3 SMAD4 TGFB1
48 11.5 SMAD2 SMAD3 SMAD4 SMAD7 SPP1 TGFB1
49 11.3 SMAD2 SMAD3 SMAD4 TGFB1
50
Show member pathways
11.25 SMAD4 SMAD7 TGFB1

GO Terms for Nephrogenic Systemic Fibrosis

Cellular components related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 CCL7 CTGF CXCL2 DCN EDN1 EPO
2 extracellular matrix GO:0031012 9.73 DCN TGFB1 TGM2 TIMP1
3 transcription factor complex GO:0005667 9.67 SMAD2 SMAD3 SMAD4 SMAD7
4 platelet alpha granule lumen GO:0031093 9.58 F13A1 TGFB1 TIMP1
5 activin responsive factor complex GO:0032444 9.26 SMAD2 SMAD4
6 heteromeric SMAD protein complex GO:0071144 8.96 SMAD2 SMAD3
7 SMAD protein complex GO:0071141 8.8 SMAD2 SMAD3 SMAD4
8 extracellular region GO:0005576 10.02 CCL7 CTGF CXCL2 DCN EDN1 EPO

Biological processes related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 CCL7 CTGF EPO TGFB1
2 cytokine-mediated signaling pathway GO:0019221 9.97 CXCL2 DCN F13A1 PIK3CA TGFB1 TIMP1
3 positive regulation of cell migration GO:0030335 9.96 CCL7 EDN1 SMAD3 TGFB1
4 in utero embryonic development GO:0001701 9.96 EDN1 EDNRA SMAD2 SMAD3 SMAD4
5 response to lipopolysaccharide GO:0032496 9.95 CXCL2 DCN EDN1 EPO
6 aging GO:0007568 9.93 CTGF DCN EPO TGFB1 TIMP1
7 response to organic substance GO:0010033 9.89 SPP1 TGFB1 TIMP1
8 BMP signaling pathway GO:0030509 9.89 SMAD4 SMAD7 TGFB1
9 extracellular matrix disassembly GO:0022617 9.87 DCN SPP1 TIMP1
10 response to glucose GO:0009749 9.86 CTGF SMAD2 TGFB1
11 regulation of signaling receptor activity GO:0010469 9.86 CCL7 CTGF CXCL2 EDN1 EPO SPP1
12 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.85 SMAD2 SMAD3 SMAD7 TGFB1
13 SMAD protein signal transduction GO:0060395 9.83 SMAD2 SMAD3 SMAD4 TGFB1
14 transforming growth factor beta receptor signaling pathway GO:0007179 9.83 SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
15 cellular response to transforming growth factor beta stimulus GO:0071560 9.81 EDN1 SMAD3 SMAD7 TGFB1
16 response to hypoxia GO:0001666 9.8 EDN1 EDNRA EPO SMAD3 SMAD4 TGFB1
17 positive regulation of epithelial to mesenchymal transition GO:0010718 9.78 SMAD2 SMAD3 SMAD4 TGFB1
18 gastrulation GO:0007369 9.77 SMAD2 SMAD3 SMAD4
19 developmental growth GO:0048589 9.77 SMAD2 SMAD3 SMAD4
20 wound healing GO:0042060 9.77 DCN SMAD2 SMAD3 TGFB1 TIMP1
21 ureteric bud development GO:0001657 9.76 SMAD2 SMAD3 SMAD7 TGFB1
22 cell activation GO:0001775 9.72 TGFB1 TIMP1
23 activin receptor signaling pathway GO:0032924 9.72 SMAD2 SMAD3
24 pathway-restricted SMAD protein phosphorylation GO:0060389 9.71 SMAD7 TGFB1
25 secondary palate development GO:0062009 9.71 SMAD2 SMAD4
26 lens fiber cell differentiation GO:0070306 9.71 SMAD3 TGFB1
27 endoderm development GO:0007492 9.71 SMAD2 SMAD3 SMAD4 TGFB1
28 positive regulation of SMAD protein signal transduction GO:0060391 9.7 SMAD4 TGFB1
29 response to dexamethasone GO:0071548 9.7 EDN1 EPO
30 artery smooth muscle contraction GO:0014824 9.68 EDN1 EDNRA
31 response to cholesterol GO:0070723 9.68 SMAD2 TGFB1
32 nodal signaling pathway GO:0038092 9.68 SMAD2 SMAD3
33 primary miRNA processing GO:0031053 9.68 SMAD2 SMAD3
34 response to transforming growth factor beta GO:0071559 9.67 EDN1 SMAD4
35 pericardium development GO:0060039 9.67 SMAD2 SMAD3
36 embryonic foregut morphogenesis GO:0048617 9.67 SMAD2 SMAD3
37 response to laminar fluid shear stress GO:0034616 9.66 SMAD7 TGFB1
38 regulation of glucose transmembrane transport GO:0010827 9.65 EDN1 EDNRA
39 common-partner SMAD protein phosphorylation GO:0007182 9.64 SMAD2 TGFB1
40 regulation of striated muscle tissue development GO:0016202 9.63 SMAD3 TGFB1
41 response to salt GO:1902074 9.63 EDN1 TGFB1
42 positive regulation of extracellular matrix assembly GO:1901203 9.62 SMAD3 TGFB1
43 positive regulation of odontogenesis GO:0042482 9.61 EDN1 TGFB1
44 regulation of transforming growth factor beta2 production GO:0032909 9.61 SMAD3 SMAD4
45 evasion or tolerance of host defenses by virus GO:0019049 9.58 SMAD3 TGFB1
46 paraxial mesoderm morphogenesis GO:0048340 9.58 SMAD2 SMAD3
47 SMAD protein complex assembly GO:0007183 9.46 SMAD2 SMAD3 SMAD4 TGFB1
48 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.35 SMAD2 SMAD3 SMAD4 SMAD7 TGFB1
49 regulation of binding GO:0051098 8.92 SMAD2 SMAD3 SMAD4 TGFB1
50 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 DCN EDN1 SMAD2 SMAD3 SMAD4 SMAD7

Molecular functions related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 transforming growth factor beta receptor binding GO:0005160 9.58 SMAD2 SMAD3 TGFB1
2 collagen binding GO:0005518 9.56 DCN SMAD3 SMAD4 SMAD7
3 enhancer binding GO:0035326 9.51 SMAD2 SMAD3
4 R-SMAD binding GO:0070412 9.5 SMAD2 SMAD3 SMAD4
5 co-SMAD binding GO:0070410 9.49 SMAD2 SMAD3
6 protein-glutamine gamma-glutamyltransferase activity GO:0003810 9.48 F13A1 TGM2
7 primary miRNA binding GO:0070878 9.46 SMAD2 SMAD3
8 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.43 SMAD2 SMAD3
9 I-SMAD binding GO:0070411 9.33 SMAD2 SMAD4 SMAD7
10 cytokine activity GO:0005125 9.17 CCL7 CXCL2 EDN1 EPO SPP1 TGFB1
11 type I transforming growth factor beta receptor binding GO:0034713 9.13 SMAD2 SMAD7 TGFB1
12 protein binding GO:0005515 10.32 CCL7 CTGF CXCL2 DCN EDN1 EDNRA

Sources for Nephrogenic Systemic Fibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....